Giuseppe La Regina


Titolo Pubblicato in Anno
Metabolic Rewiring in Cancer: Small Molecule Inhibitors in Colorectal Cancer Therapy MOLECULES 2024
RS6077 induces mitotic arrest and selectively activates cell death in human cancer cell lines and in a lymphoma tumor in vivo EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2023
A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations MOLECULES 2023
Targeting the Grb2 cSH3 domain: design, synthesis and biological evaluation of the first series of modulators BIOORGANIC CHEMISTRY 2023
Novel N-(Heterocyclylphenyl)benzensulfonamide Sharing an Unreported Binding Site with T-Cell Factor 4 at the β-Catenin Armadillo Repeats Domain as an Anticancer Agent ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE 2023
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment MOLECULES 2023
Rimonabant-Based Compounds Bearing Hydrophobic Amino Acid Derivatives as Cannabinoid Receptor Subtype 1 Ligands ACS MEDICINAL CHEMISTRY LETTERS 2023
4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)benzenesulfonamide, a Novel Carbonic Anhydrase and Wnt/β-Catenin Signaling Pathway Dual-Targeting Inhibitor with Potent Activity against Multidrug Resistant Cancer Cells JOURNAL OF MEDICINAL CHEMISTRY 2023
Biological evaluation of [4‐(4‐aminophenyl)‐1‐(4‐fluorophenyl)‐1H‐pyrrol‐3‐yl](3,4,5‐trimethoxyphenyl)methanone as potential antineoplastic agent in 2D and 3D breast cancer models ARCHIV DER PHARMAZIE 2023
Anticancer activity of (S)-5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-oxo-1-((pyridin-4-ylmethyl)amino)propan-2-yl)-1H-indole-2-carboxamide (RS4690), a new dishevelled 1 inhibitor CANCERS 2022
Single-run chemo- and enantio-selective high-performance liquid chromatography separation of tramadol and its principal metabolite, O-desmethyltramadol, using a chlorinated immobilized amylose-based chiral stationary phase under multimodal elution conditions SEPARATION SCIENCE PLUS 2022
An innovation 10 years in the making: the stories in the pages of ACS Medicinal Chemistry Letters ACS MEDICINAL CHEMISTRY LETTERS 2022
Modulating undruggable targets to overcome cancer therapy resistance DRUG RESISTANCE UPDATES 2022
Discovery of novel human lactate dehydrogenase inhibitors: Structure-based virtual screening studies and biological assessment EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2022
Induction of Ferroptosis in Glioblastoma and Ovarian Cancers by a New Pyrrole Tubulin Assembly Inhibitor JOURNAL OF MEDICINAL CHEMISTRY 2022
Emerging Direct Targeting β-Catenin Agents MOLECULES 2022
Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2021
CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme EUROPEAN JOURNAL OF PHARMACOLOGY 2021
RS4651 suppresses lung fibroblast activation via the TGF-β1/SMAD signalling pathway EUROPEAN JOURNAL OF PHARMACOLOGY 2021
RS-5645 attenuates inflammatory cytokine storm induced by SARS-CoV-2 spike protein and LPS by modulating pulmonary microbiota INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES 2021


  • LS1_13
  • PE5_17
  • PE5_18


  • Life-science technologies & biotechnologies

Interessi di ricerca

Progettazione, sintesi e sviluppo di agenti anti-infettivi (HIV-1, Rhinovirus, virus dell’epatite C, virus Dengue, Mycobacterium tuberculosis, Candida albicans), anti-tumorali (tubulina, apoptosi, istone demetilasi, metalloproteinasi di matrice, membri della famiglia BCL-2, Frizzled4, anidrasi carbonica, indolamina 2,3-diossigenasi 1, MDM2/MDM4, NHERF1, beta-catenina) e attivi sul sistema nervoso centrale (monoammino ossidasi, sistema endocannabinoide, glicogeno sintasi chinasi 3 beta); sintesi microonde-assistita; studi di modellistica molecolare.


drug design and discovery
Anti-Infective Agents
anticancer agent

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma